Endocrinology · Pancreatic Neuroendocrine Tumors
The facts most likely to be tested
Glucagonoma is a rare pancreatic alpha-cell tumor that results in the excessive secretion of glucagon.
The pathognomonic dermatologic finding is necrolytic migratory erythema, characterized by erythematous, blistering, and crusting plaques in intertriginous areas.
Patients frequently present with the 4 Ds: dermatitis (necrolytic migratory erythema), diabetes (or glucose intolerance), deep vein thrombosis, and depression.
The diagnosis is confirmed by a significantly elevated serum glucagon level, typically exceeding 500 pg/mL.
Weight loss, anemia of chronic disease, and glossitis or cheilitis are common systemic manifestations of the catabolic state induced by hyperglucagonemia.
Abdominal CT or MRI is the imaging modality of choice to localize the tumor, which is most commonly located in the pancreatic tail.
Definitive management for localized disease is surgical resection, while octreotide is used to manage symptoms and inhibit glucagon secretion in unresectable cases.
Vignette unlocked
A 58-year-old female presents with a persistent, painful rash on her groin and thighs that has been waxing and waning for six months. She reports a 15-lb unintentional weight loss, fatigue, and a recent diagnosis of mild hyperglycemia. Physical examination reveals erythematous, blistering plaques with central clearing and crusting in the perineal region and glossitis. Laboratory studies demonstrate a normocytic anemia and a fasting glucose of 135 mg/dL.
What is the most likely diagnosis?
Glucagonoma
The patient's presentation of necrolytic migratory erythema, new-onset diabetes, and weight loss is classic for glucagonoma, which is confirmed by elevated serum glucagon levels.
Full handout
High yield triage
Etiology / Epidemiology
Rare pancreatic neuroendocrine tumor (pNET) arising from alpha cells, typically in the pancreatic tail.
Clinical Manifestations
Classic triad: necrolytic migratory erythema, diabetes mellitus, and weight loss.
Diagnosis
Elevated plasma glucagon levels (>500 pg/mL) and CT/MRI for tumor localization.
Treatment
Surgical resection is curative; octreotide manages symptoms pre-operatively.
Prognosis
Often malignant at diagnosis with metastasis to the liver; 5-year survival varies by stage.
Full handout
Epidemiology & Etiology
Glucagonomas are rare, slow-growing tumors of the pancreatic alpha cells. They are frequently associated with MEN1 syndrome, necessitating screening for other endocrine tumors. Most patients are diagnosed between ages 40 and 60.
Pertinent Anatomy
The tumor is most commonly located in the pancreatic tail. This location often allows for distal pancreatectomy during surgical management.
Pathophysiology
Excessive glucagon secretion leads to profound catabolism, causing muscle wasting and weight loss. The hyperglucagonemia induces hepatic gluconeogenesis and glycogenolysis, resulting in secondary diabetes mellitus. The characteristic skin rash is thought to be secondary to amino acid deficiency and zinc deficiency caused by the catabolic state.
Clinical Manifestations
The hallmark is necrolytic migratory erythema, a painful, blistering rash typically involving the groin, perineum, and extremities. Patients present with the '4 Ds': Dermatitis (rash), Diabetes, DVT (thromboembolism), and Depression. Thromboembolism is a significant cause of morbidity and mortality in these patients.
Diagnosis
Diagnosis is confirmed by plasma glucagon levels >500 pg/mL in the presence of characteristic clinical findings. CT abdomen with contrast or MRI is the gold standard for tumor localization. Avoid biopsy of the primary tumor if possible to prevent seeding.
Treatment
Surgical resection is the only curative treatment. Octreotide (a somatostatin analog) is the first-line medical therapy to inhibit glucagon release and improve the skin rash. Zinc supplementation is often required to resolve the dermatologic manifestations.
Prognosis
Approximately 70-80% of patients have metastatic disease at the time of diagnosis, most commonly to the liver. Long-term monitoring for recurrence is essential. Surgical debulking may be performed even in metastatic cases to reduce hormonal symptoms.
Differential Diagnosis
Pellagra: presents with dermatitis and diarrhea but lacks hyperglucagonemia
Zinc deficiency: presents with similar rash but lacks elevated glucagon
Necrolytic acral erythema: associated with Hepatitis C, not pancreatic tumors
Type 2 Diabetes: lacks the pathognomonic skin rash
VIPoma: presents with watery diarrhea (WDHA syndrome) rather than rash